VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Up 470.4% in June

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 113,911 shares, an increase of 470.4% from the June 15th total of 19,972 shares. Based on an average trading volume of 157,314 shares, the days-to-cover ratio is currently 0.7 days. Approximately 4.5% of the company’s shares are sold short.

VivoSim Labs Stock Performance

Shares of VIVS stock traded up $0.08 on Friday, hitting $0.88. The company had a trading volume of 937,322 shares, compared to its average volume of 121,012. VivoSim Labs has a twelve month low of $0.78 and a twelve month high of $5.30. The firm has a market cap of $2.29 million, a P/E ratio of -0.28 and a beta of 1.40. The stock’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Trading of VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the Securities and Exchange Commission. 8.23% of the stock is owned by hedge funds and other institutional investors.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.